Protein microarray technology: Assisting personalized medicine in oncology (Review)
- Authors:
- Monica Neagu
- Marinela Bostan
- Carolina Constantin
-
Affiliations: Department of Immunology, ‘Victor Babes’ National Institute of Pathology, 050096 Bucharest, Romania - Published online on: June 12, 2019 https://doi.org/10.3892/wasj.2019.15
- Pages: 113-124
This article is mentioned in:
Abstract
 |
 |
 |
|
Schena M, Shalon D, Davis RW and Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270:467–470. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Gygi SP, Rochon Y, Franza BR and Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 19:1720–1730. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Haab BB: Antibody arrays in cancer research. Mol Cell Proteomics. 4:377–383. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Chen CS and Zhu H: Protein microarrays. Biotechniques. 40(423, 425, 427)2006.PubMed/NCBI View Article : Google Scholar | |
|
Kopf E and Zharhary D: Antibody arrays-An emerging tool in cancer proteomics. Int J Biochem Cell Biol. 39:1305–1317. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Constantin C, Surcel M, Munteanu A and Neagu M: Protein microarray technology for antibody detection associated to human pathology. Roman Arch Microbiol Immunol. 77:236–244. 2018. | |
|
Poetz O, Schwenk JM, Kramer S, Stoll D, Templin MF and Joos TO: Protein microarrays: Catching the proteome. Mech Ageing Dev. 126:161–170. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA and Petricoin EF III: Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics. 4:157–164. 2007.PubMed/NCBI | |
|
Matei C, Tampa M, Ion RM, Georgescu SR, Dumitrascu GR, Constantin C and Neagu M: Protein microarray for complex apoptosis monitoring of dysplastic oral keratinocytes in experimental photodynamic therapy. Biol Res. 47(33)2014.PubMed/NCBI View Article : Google Scholar | |
|
Demyanenko SV, Uzdensky AB, Sharifulina SA, Lapteva TO and Polyakova LP: PDT-induced epigenetic changes in the mouse cerebral cortex: A protein microarray study. Biochim Biophys Acta. 1840:262–270. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Sutandy FX, Qian J, Chen CS and Zhu H: Overview of protein microarrays. Curr Protoc Protein Sci. 27:Unit 27.1. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wilson JJ, Burgess R, Mao YQ, Luo S, Tang H, Jones VS, Weisheng B, Huang RY, Chen X and Huang RP: Antibody arrays in biomarker discovery. Adv Clin Chem. 69:255–324. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Díez P, Dasilva N, González-González M, Matarraz S, Casado-Vela J, Orfao A and Fuentes M: Data analysis strategies for protein microarrays. Microarrays (Basel). 1:64–83. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Angenendt P, Kreutzberger J, Glökler J and Hoheisel JD: Generation of high density protein microarrays by cell-free in situ expression of unpurified PCR products. Mol Cell Proteomics. 5:1658–1666. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Schweitzer B, Predki P and Snyder M: Microarrays to characterize protein interactions on a whole-proteome scale. Proteomics. 3:2190–2199. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Alhamdani MS, Schröder C and Hoheisel JD: Oncoproteomic profiling with antibody microarrays. Genome Med. 1(68)2009.PubMed/NCBI View Article : Google Scholar | |
|
Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA and Petricoin EF III: Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics. 3:2085–2090. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Yuk CS, Lee HK, Kim HT, Choi YK, Lee BC, Chun BH and Chung N: Development and evaluation of a protein microarray chip for diagnosis of hepatitis C virus. Biotechnol Lett. 26:1563–1568. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Gowan SM, Hardcastle A, Hallsworth AE, Valenti MR, Hunter LJ, de Haven Brandon AK, Garrett MD, Raynaud F, Workman P, Aherne W and Eccles SA: Application of meso scale technology for the measurement of phosphoproteins in human tumour xenografts. Assay Drug Dev Technol. 5:391–401. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S and Maio M: Epigenetics of human cutaneous melanoma: Setting the stage for new therapeutic strategies. J Transl Med. 8(56)2010.PubMed/NCBI View Article : Google Scholar | |
|
Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N and Yamada T: Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn J Clin Oncol. 43:103–109. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Yang L, Guo S, Li Y, Zhou S and Tao S: Protein microarrays for systems biology. Acta Biochim Biophys Sin (Shanghai). 43:161–71. 2011.PubMed/NCBI View Article : Google Scholar | |
|
LaBaer J and Ramachandran N: Protein microarrays as tools for functional proteomics. Curr Opin Chem Biol. 9:14–19. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Hu S, Xie Z, Qian J, Blackshaw S and Zhu H: Functional protein microarray technology. Wiley Interdiscip Rev Syst Biol Med. 3:255–268. 2011.PubMed/NCBI View Article : Google Scholar | |
|
He M, Stoevesandt O and Taussig MJ: In situ synthesis of protein arrays. Curr Opin Biotechnol. 19:4–9. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Tao SC and Zhu H: Protein chip fabrication by capture of nascent polypeptides. Nat Biotechnol. 24:1253–1254. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Miersch S and LaBaer J: Nucleic acid programmable protein arrays: Versatile tools for array-based functional protein studies. Curr Protoc Protein Sci Chapter. 27:Unit27.2. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Wright C, Sibani S, Trudgian D, Fischer R, Kessler B, LaBaer J and Bowness P: Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics. 11:M9 00384. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Neagu M and Constantin C: Immunogenicity of Stem Cell in Tumorigenesis Versus Regeneration. In: Stem Cells between Regeneration and Tumorigenesis. Tanase C and Neagu M (eds). Bentham Pbl. House. pp202–234. 2016. View Article : Google Scholar | |
|
Chiodoni C, Di Martino MT, Zazzeroni F, Caraglia M, Donadelli M, Meschini S, Leonetti C and Scotlandi K: Cell communication and signalling: How to turn bad language into positive one. J Exp Clin Cancer Res. 38(128)2019.PubMed/NCBI View Article : Google Scholar | |
|
James P: Protein identification in the post-genome era: The rapid rise of proteomics. Q Rev Biophys. 30:279–331. 1997.PubMed/NCBI | |
|
Joos T and Bachmann J: Protein microarrays: Potentials and limitations. Front Biosci (Landmark Ed). 14:4376–4385. 2009.PubMed/NCBI | |
|
Ramachandran N, Raphael JV, Hainsworth E, Demirkan G, Fuentes MG, Rolfs A, Hu Y and LaBaer J: Next-generation high-density self-assembling functional protein arrays. Nat Methods. 5:535–538. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Manzano-Romána R and Fuentes M: A decade of nucleic acid programmable protein arrays (NAPPA) availability: News, actors, progress, prospects and access. J Proteomics. 198:27–35. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rivera R, Wang J, Yu X, Demirkan G, Hopper M, Bian X, Tahsin T, Magee DM, Qiu J, LaBaer J and Wallstrom G: Automatic identification and quantification of extra-well fluorescence in microarray images. J Proteome Res. 16:3969–3977. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Yu X, Petritis B, Duan H, Xu D and LaBaer J: Advances in cell-free protein array methods. Expert Rev Proteomics. 15:1–11. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yu X, Song L, Petritis B, Bian X, Wang H, Viloria J, Park J, Bui H, Li H, Wang J, et al: Multiplexed nucleic acid programmable protein arrays. Theranostics. 7:4057–4070. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Bulman A, Neagu M and Constantin C: Immunomics in skin cancer-improvement in diagnosis, prognosis and therapy monitoring. Curr Proteomics. 10:202–217. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Neagu M and Constantin C: New Insights in Cutaneous Melanoma Immune-Therapy-Tackling Immune-Suppression and Specific Anti-Tumoral Response. In: Melanoma. Murph M (ed). IntechOpen. pp225–246. 2015. View Article : Google Scholar | |
|
Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, et al: Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 9:998–1008. 2003.PubMed/NCBI | |
|
Yuan J, Wang E and Fox BA: Immune monitoring technology primer: Protein microarray (‘seromics’). J Immunother Cancer. 4(2)2016.PubMed/NCBI View Article : Google Scholar | |
|
Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Fulton KM and Twine SM: Immunoproteomics: Current technology and applications. Methods Mol Biol. 1061:21–57. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:11810–11813. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Ladd JJ, Chao T, Johnson MM, Qiu J, Chin A, Israel R, Pitteri SJ, Mao J, Wu M, Amon LM, et al: Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res. 73:1502–1513. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Madoz-Gurpide J, Kuick R, Wang H, Misek DE and Hanash SM: Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics. 7:268–281. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold LA, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, et al: Microarrays of tumour cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics. 3:2200–2207. 2003. View Article : Google Scholar | |
|
GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, et al: Humoral immune response against nontargeted tumour antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 21:3619–3630. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ and Fong L: Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 189:3759–3766. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Graff JN, Puri S, Bifulco CB, Fox BA and Beer TM: Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res. 2:399–403. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Gnjatic S, Ritter E, Büchler MW, Giese NA, Brors B, Frei C, Murray A, Halama N, Zörnig I, Chen YT, et al: Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA. 107:5088–5093. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Abel L, Kutschki S, Turewicz M, Eisenacher M, Stoutjesdijk J, Meyer HE, Woitalla D and May C: Autoimmune profiling with protein microarrays in clinical applications. Biomed Biochim Acta. 1844:977–987. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Turewicz M, May C, Ahrens M, Woitalla D, Gold R, Casjens S, Pesch B, BrüningT Meyer HE, Nordhoff E, et al: Improving the default data analysis workflow for large autoimmune biomarker discovery studies with ProtoArrays. Proteomics. 13:2083–2087. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Zhang DY, Ye F, Gao L, Liu X, Zhao X, Che Y, Wang H, Wang L, Wu J, Song D, et al: Proteomics, pathway array and signaling network-based medicine in cancer. Cell Div. 4(20)2009.PubMed/NCBI View Article : Google Scholar | |
|
Schumacher S, Muekusch S and Seitz H: Up-to-date applications of microarrays and their way to commercialization. Microarrays (Basel). 4:196–213. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ayoglu B, Schwenk JM and Nilsson P: Antigen arrays for profiling autoantibody repertoires. Bioanalysis. 8:1105–1126. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Stoevesandt O, Taussig MJ and He M: Protein microarrays: High-throughput tools for proteomics. Expert Rev Proteomics. 6:145–157. 2009.PubMed/NCBI View Article : Google Scholar | |
|
No authors listed. The call of the human proteome. Nat Methods. 7(661)2010.PubMed/NCBI | |
|
Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, Bergeron J, Borchers CH, Corthals GL, Costello CE, et al: The human proteome project: Current state and future direction. Mol Cell Proteomics. 10:M111.009993. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Jantsch MF, Quattrone A, O'Connell M, Helm M, Frye M, Macias-Gonzales M, Ohman M, Ameres S, Willems L, Fuks F, et al: Positioning Europe for the EPITRANSCRIPTOMICS challenge. RNA Biol. 15:829–831. 2018.PubMed/NCBI View Article : Google Scholar | |
|
González-Gomariz J, Guruceaga E, López-Sánchez M and Segura V: Proteogenomics in the context of the human proteome project (HPP). Expert Rev Proteomics. 16:267–275. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tanase C, Albulescu R and Neagu M: Updates in immune-based multiplex assays. J Immunoassay Immunochem. 40:1–2. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Popa ML, Albulescu R, Neagu M, Eugen Hinescu ME and Tanase C: Multiplex assay for multiomics advances in personalized-precision medicine. J Immunoassay Immunochem. 40:3–25. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et al: Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 124:2785–2800. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Smith ER: A two-tiered health care system: Is there anything new? Can J Cardiol. 23:915–916. 2007.(In English; French). PubMed/NCBI | |
|
Alyass A, Turcotte M and Meyre D: From big data analysis to personalized medicine for all: Challenges and opportunities. BMC Med Genomics. 8(33)2015. View Article : Google Scholar | |
|
Fröhlich H, Balling R, Beerenwinkel N, Kohlbacher O, Kumar S, Lengauer T, Maathuis MH, Moreau Y, Murphy SA, Przytycka TM, et al: From hype to reality: Data science enabling personalized medicine. BMC Med. 16(150)2018.PubMed/NCBI View Article : Google Scholar | |
|
Wong SH: Pharmacogenomics and personalized medicine. In: Handbook of drug monitoring methods: Therapeutics and drugs of abuse. Dasgupta A (ed). Humana Press, New York, NY. pp211–223. 2007. | |
|
Yu X, Schneiderhan-Marra N and Joos TO: Protein microarrays for personalized medicine. Clin Chem. 56:376–387. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Masuda M and Yamada T: Signalling pathway profiling by reverse-phase protein array for personalized cancer medicine. Biochim Biophys Acta. 1854:651–657. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Rosa M: Advances in the molecular analysis of breast cancer: Pathway toward personalized medicine. Cancer Control. 22:211–219. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kim DC, Wang X, Yang CR and Gao JX: A framework for personalized medicine: Prediction of drug sensitivity in cancer by proteomic profiling. Proteome Sci. 10 (Suppl 1)(S13)2012.PubMed/NCBI View Article : Google Scholar | |
|
Wistuba II, Gelovani JG, Jacoby JJ, Davis SE and Herbst RS: Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol. 8:135–141. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mueller C, Liotta L and Espina V: Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol. 4:461–481. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR and Mills GB: Functional proteomic profiling of AML predicts response and survival. Blood. 113:154–164. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Cain JW, Hauptschein RS, Stewart JK, Bagci T, Sahagian GG and Jay DG: Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology. Mol Cancer Res. 9:637–647. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J and Petricoin EF III: Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell. 3:317–325. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Spurrier B, Ramalingam S and Nishizuka S: Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc. 3:1796–1808. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kim YB, Yang CR and Gao J: Functional proteomic pattern identification under low dose ionizing radiation. Artif Intell Med. 49:177–185. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Dong Y, Jiwani AJ, Zou Y, Pastor J, Kuro OM, Habib AA, Ruan M, Boothman DA and Yang CR: Improved protein arrays for quantitative systems analysis of the dynamics of signaling pathway interactions. Proteome Sci. 9(53)2011.PubMed/NCBI View Article : Google Scholar | |
|
Laforte V, Lo PS, Li H and Juncker D: Antibody colocalization microarray for cross-reactivity-free multiplexed protein analysis. Methods Mol Biol. 1619:239–261. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros LJ, Szankasi P and Elenitoba-Johnson KS: The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood. 114:1585–1595. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki NK, Ferrara CA, Hepburne-Scott H, Joyce S, Koopman J, et al: Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods. 341:50–58. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gaudreau PO, Peng D, Rodriguez BL, Fradette J, Gibson L, Kundu S, Chen L, et al: Co-clinical trials of MEK inhibitor, anti PD-L1 and anti CTLA-4 combination treatment in non-small cell lung cancer. J ImmunoTherapy Cancer. 6 (Suppl 1)(S114)2018. | |
|
Vilgelm AE, Johnson DB and Richmond A: Combinatorial approach to cancer immunotherapy: Strength in numbers. J Leukoc Biol. 100:275–290. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Terracciano R, Pelaia G, Preianò M and Savino R: Asthma and COPD proteomics: Current approaches and future directions. Proteomics Clin Appl. 9:203–220. 2015. View Article : Google Scholar | |
|
Vizcaino JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, et al: 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44(11033)2016.PubMed/NCBI View Article : Google Scholar | |
|
Hamsten C, Häggmark A, Grundström J, Mikus M, Lindskog C, Konradsen JR, Eklund A, Pershagen G, Wickman M, Grunewald J, et al: Protein profiles of CCL5, HPGDS, and NPSR1 in plasma reveal association with childhood asthma. Allergy. 71:1357–1361. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Gharib SA, Nguyen EV, Lai Y, Plampin JD, Goodlett DR and Hallstrand TS: Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol. 128:1176–1184, e1176. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Ohlmeier S, Nieminen P, Gao J, Kanerva T, Rönty M, Toljamo T, Bergmann U, Mazur W and Pulkkinen V: Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 310:L1155–L1165. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Barnes PJ: Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 131:636–645. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Levitt JE and Rogers AJ: Proteomic study of acute respiratory distress syndrome: Current knowledge and implications for drug development. Expert Rev Proteomics. 13:457–469. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Priyadharshini VS and Teran LM: Personalized medicine in respiratory disease: Role of proteomics. Adv Protein Chem Struct Biol. 102:115–146. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Foster MW, Morrison LD, Todd JL, Snyder LD, Thompson JW, Soderblom EJ, Plonk K, Weinhold KJ, Townsend R, Minnich A and Moseley MA: Quantitative proteomics of bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. J Proteome Res. 14:1238–1249. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, Caruso P, Southwood M, Foster WS, Morrell NW and Stewart DJ: Proteomic analysis implicates translationally controlled tumour protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation. 129:2125–2135. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ and Wilkins MR: Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation. 122:2058–2067. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Kan M, Shumyatcher M and Himes BE: Using omics approaches to understand pulmonary diseases. Respir Res. 18(149)2017.PubMed/NCBI View Article : Google Scholar | |
|
Cohen AS, Khalil FK, Welsh EA, Schabath MB, Enkemann SA, Davis A, Zhou JM, Boulware DC, Kim J, Haura EB and Morse DL: Cell-surface marker discovery for lung cancer. Oncotarget. 8:113373–113402. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Monette A, Bergeron D, Ben Amor A, Meunier L, Caron C, Mes-Masson AM, Kchir N, Hamzaoui K, Jurisica I and Lapointe R: Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. J Immunother Cancer. 7(86)2019.PubMed/NCBI View Article : Google Scholar | |
|
Schwill M, Tamaskovic R, Gajadhar AS, Kast F, White FM and Plückthun A: Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer. Sci Signal. 12:eaau2875. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, et al: Dual mTOR kinase inhibitor MLN0128 sensitizes HR+/HER2+ breast cancer patient-derived xenografts to trastuzumab or fulvestrant. Clin Cancer Res. 24:395–406. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lee J, Geiss GK, Demirkan G, Vellano CP, Filanoski B, Lu Y, Ju Z, Yu S, Guo H, Bogatzki LY, et al: Implementation of a multiplex and quantitative proteomics platform for assessing protein lysates using DNA-barcoded antibodies. Mol Cell Proteomics. 17:1245–1258. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kars MD and Yıldırım G: Determination of the target proteins in chemotherapy resistant breast cancer stem cell-like cells by protein array. Eur J Pharmacol. 848:23–29. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Li M, Li H, Liu F, Bi R, Tu X, Chen L, Ye S and Cheng X: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: Implications for personalized cancer therapy. J Ovarian Res. 10(9)2017.PubMed/NCBI View Article : Google Scholar | |
|
Mabuchi S, Sugiyama T and Kimura T: Clear cell carcinoma of the ovary: Molecular insights and future therapeutic perspectives. J Gynecol Oncol. 27(e31)2016.PubMed/NCBI View Article : Google Scholar | |
|
Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K and Okamoto A: Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signalling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. 55:832–841. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Yamashita Y: Ovarian cancer: New developments in clear cell carcinoma and hopes for targeted therapy. Jpn J Clin Oncol. 45:405–407. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, et al: Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy. Proteomics. 15:365–373. 2015.PubMed/NCBI View Article : Google Scholar | |
|
di Martino S, De Luca G, Grassi L, Federici G, Alfonsi R, Signore M, Addario A, De Salvo L, Francescangeli F, Sanchez M, et al: Renal cancer: New models and approach for personalizing therapy. J Exp Clin Cancer Res. 37(217)2018.PubMed/NCBI View Article : Google Scholar | |
|
Hoff FW, Hu CW, Qiu Y, Ligeralde A, Yoo SY, Mahmud H, de Bont ESJM, Qutub AA, Horton TM and Kornblau SM: Recognition of recurrent protein expression patterns in pediatric acute myeloid leukemia identified new therapeutic targets. Mol Cancer Res. 16:1275–1286. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, et al: Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: A phase II study. Clin Lymphoma Myeloma Leuk. S2152-2650:31542–31548. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yang Q, Bavi P, Wang JY and Roehrl MH: Immuno-proteomic discovery of tumour tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. J Proteomics. 168:53–65. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hagman H, Bendahl PO, Lidfeldt J, Belting M and Johnsson A: Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer. PLoS One. 13(e0209838)2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu P, Souma T, Wei AZ, Xie X, Luo X and Jin J: Personalized peptide arrays for detection of HLA alloantibodies in organ transplantation. J Vis Exp. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Soni A, Gowthamarajan K and Radhakrishnan A: Personalized medicine and customized drug delivery systems: The new trend of drug delivery and disease management. Int J Pharm Compd. 22:108–121. 2018.PubMed/NCBI | |
|
Syafrizayanti Lueong SS, Di C, Schaefer JV, Plückthun A and Hoheisel JD: Personalised proteome analysis by means of protein microarrays made from individual patient samples. Sci Rep. 7(39756)2017.PubMed/NCBI View Article : Google Scholar |
